{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:31:48Z","timestamp":1777901508440,"version":"3.51.4"},"reference-count":3,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1988,6,1]],"date-time":"1988-06-01T00:00:00Z","timestamp":581126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scott Med J"],"published-print":{"date-parts":[[1988,6]]},"abstract":"<jats:p>Phenytoin is an established therapy for post-herpetic neuralgia. In order to maintain serum phenytoin levels in the normal therapeutic range, serum phenytoin monitoring is required. This range may, however, be misleading in certain clinical conditions. We report here a patient with hypoalbuminaemia who developed marked clinical phenytoin toxicity despite maintenance of the serum total phenytoin concentration within the therapeutic range.<\/jats:p>","DOI":"10.1177\/003693308803300305","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T01:34:10Z","timestamp":1484098450000},"page":"267-268","source":"Crossref","is-referenced-by-count":1,"title":["Phenytoin Monitoring: Clinical or Scientific?"],"prefix":"10.1177","volume":"33","author":[{"given":"J. D.","family":"Fulton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"McGovern","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Stobhill General Hospital, Glasgow G21 3UW"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. N.","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Carlile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1988,6,1]]},"reference":[{"key":"bibr1-003693308803300305","first-page":"191","volume":"14","author":"Taub A.","year":"1984","journal-title":"Drug therapy"},{"key":"bibr2-003693308803300305","unstructured":"Hatangdi VS, Boas RA, Richards EG. Post-herpetic neuralgia: Management with anti-epileptic and tricyclic drugs. In: Bonica JJ, Albe-Fessard D. Advances in Pain Research and Therapy Vol. New York, Raven Press 1976. pp 583\u20137."},{"key":"bibr3-003693308803300305","unstructured":"Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. San Francisco: Applied Therapeutics 1980. pp 275\u2013314."}],"container-title":["Scottish Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/003693308803300305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/003693308803300305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:03:13Z","timestamp":1777633393000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/003693308803300305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,6]]},"references-count":3,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1988,6]]}},"alternative-id":["10.1177\/003693308803300305"],"URL":"https:\/\/doi.org\/10.1177\/003693308803300305","relation":{},"ISSN":["0036-9330","2045-6441"],"issn-type":[{"value":"0036-9330","type":"print"},{"value":"2045-6441","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,6]]}}}